MiNK Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
MiNK Therapeutics, Inc. (INKT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $7.21 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.21, a 63.77% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $19.90, a 772.81% increase year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.28, a 24.75% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.03.
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $13.46, a 40.84% decline from fiscal 2024.
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $22.75, a 655.81% increase from fiscal 2023.
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $3.01, a 437.50% increase from fiscal 2022.
- MiNK Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $0.56.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.21 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $7.21 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $13.46 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $13.46 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $13.31 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $19.90 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $22.75 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $2.27 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $2.27 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $2.28 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $3.01 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $3.03 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $3.03 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $3.03 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $0.56 10-K · filed 2023-03-24 | |||
| 2022-09-30 | $0.44 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $0.68 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |